Pancreaticoduodenectomy (PD) is one of the most difficult procedures in general surgery which involves the removal and reconstruction of many organs. PD is the standard surgical method for malignant tumors of the head, uncinate process and even the neck of the pancreas. During PD surgery, it often involves the removal and reconstruction of blood vessels. This is a clinical review about vascular resection and reconstruction in PD surgery.

Background RAN binding protein 3-like (RANBP3L), a member of the Ran-binding protein family, has been linked to various cellular functions, but the role in cancer remains underexplored. In this research we assessed the diagnosis and prognosis value about RANBP3L in pan-cancer, especially in liver hepatocellular carcinoma (LIHC). Methods We analyzed RANBP3L expression of 33 cancer types from TCGA data and assessed its relationship with overall survival (OS), disease-specific survival (DSS), and progression-free interval (PFI). We used TIMER2.0 and CIBERSORT to explore the correlation between RANBP3L expression and immune cells. we conducted immunohistochemistry, qRT-PCR, and western blotting by using tissue samples from LIHC patients to assess the RANBP3L’s diagnostic and prognostic value of LIHC. Results In 18 different cancers, RANBP3L expression was found to be lower in tumor tissues compared to normal tissues, including LIHC. Lower RANBP3L expression was referred to shorter OS, DSS, and PFI in LIHC. ROC analysis and nomogram model based on RANBP3L expression demonstrated high predictive accuracy for patient diagnosis and survival. Moreover, immune infiltration analysis showed that RANBP3L related to various immune cells and impacted prognosis. Furthermore, analysis on LIHC patient tissues found that higher RANBP3L expression was related to better tumor-free survival and OS. Conclusion RANBP3L plays a crucial role in LIHC. Not only does its expression level correlate with patient survival, but it also plays an important role in immune modulation. RANBP3L presents a promising candidate for future therapeutic strategies and biomarker for LIHC.